Determination of true Glia-Neuron Ratios: Validation of the Isotropic Fractionato

真实胶质细胞-神经元比率的测定:各向同性分数的验证

基本信息

  • 批准号:
    8725753
  • 负责人:
  • 金额:
    $ 7.1万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-09-01 至 2017-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Major neurological and psychiatric diseases have been reported to be associated with significantly changed glia densities, but considerable confusion surrounds the question of the true numbers and ratios of neurons and glial cells in the brains of humans and animals. Traditionally and per "textbook knowledge," it was thought that glial cells outnumber neurons by a ratio of between 10:1 and 50:1. Recently introduced new counting techniques have challenged this belief and postulate a ratio of approximately 1:1, reducing the number of glial cells in the human brain from previous estimates by as much as 4.9 trillion (from 5 trillion to a mere 100 billion). The new, much lower estimates of glial cells are primarily based on a novel methodological approach, the isotropic fractionator (IF). However, this technique has not been calibrated or validated. It is therefore uncertain whether it produces true numbers or may possibly be biased towards larger particles (neuronal nuclei) and may underestimate smaller ones (glial nuclei). The fractionator technique homogenizes whole brains (or dissected parts thereof), then takes samples of the cell nuclei in solution, and uses antibody labeling to distinguish neuronal nuclei from other nuclei such as glia in sample solutions. While conceptually elegant, it remains to be calibrated against known numbers and ratios of neurons and glial cells. Therefore, we propose a series of calibrations that will unambiguously determine the presence or absence of any biases in the isotropic fractionator (IF) technique. We will probe a variety of human and non-human primate brain regions (primarily white matter tracts) to determine whether the fractionator accurately estimates numbers of glial cells. The same brain regions will be examined by measuring DNA content (which can directly reflect cell numbers), and by histology, using systematic random sampling to independently estimate glial numbers and ratios. Preliminary data indicate that the histological approach is most suitable to provide a gold standard for comparison. Modern stereological sampling techniques will identify the ratios of cell types at the ultrastructural level. This work will clarify true neuron-glia ratios in the bain and other parts of the CNS. Validation of the new fractionator method will be crucial for understanding neurological and psychiatric diseases with reported imbalances of glia cell densities, such as schizophrenia, autism, bipolar disease, and depression.
描述(申请人提供):据报道,主要的神经和精神疾病与胶质细胞密度的显著变化有关,但人们对人类和动物大脑中神经元和胶质细胞的真实数量和比例的问题存在相当大的困惑。传统上,根据“教科书知识”,人们认为胶质细胞的数量超过神经元的比例在10:1到50:1之间。最近引入的新计数技术挑战了这一信念,并假设了大约1:1的比例,使人类大脑中神经胶质细胞的数量从先前的估计减少了4.9万亿(从5万亿减少到仅仅1000亿)。对胶质细胞的新的、低得多的估计主要基于一种新的方法学方法,即各向同性分馏器(IF)。然而,这项技术还没有得到校准或验证。因此,不确定它是产生真实的数字,还是可能偏向较大的粒子(神经元核),并可能低估较小的粒子(神经胶质核)。分割机技术将整个大脑(或其解剖部分)均质,然后提取溶液中的细胞核样本,并使用抗体标记来区分样本溶液中的神经元核和其他核,如胶质细胞。虽然在概念上是优雅的,但它仍然需要根据神经元和神经胶质细胞的已知数量和比例进行校准。因此,我们提出了一系列校准,明确地确定各向同性分馏塔(IF)技术中是否存在任何偏差。我们将探索人类和非人类灵长类动物大脑的各种区域(主要是白质束),以确定分级器是否准确地估计神经胶质细胞的数量。同样的大脑区域将通过测量DNA含量(可以直接反映细胞数量)进行检查,并通过组织学进行检查,使用系统的随机抽样独立估计神经胶质细胞的数量和比率。初步数据表明,组织学方法最适合提供比较的黄金标准。现代体视学取样技术将在超微结构水平上确定细胞类型的比率。这项工作将澄清贝恩和中枢神经其他部分的真实神经元-胶质细胞比率。新分割器方法的验证对于了解神经和精神疾病,如精神分裂症、自闭症、双相情感障碍和抑郁症等已报道的胶质细胞密度失衡至关重要。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

CHRISTOPHER S VON BARTHELD其他文献

CHRISTOPHER S VON BARTHELD的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('CHRISTOPHER S VON BARTHELD', 18)}}的其他基金

Does Ethnic Variation of the Orbit Determine the Prevalence of Horizontal Strabismus?
眼眶的种族差异是否决定了水平斜视的患病率?
  • 批准号:
    10459569
  • 财政年份:
    2021
  • 资助金额:
    $ 7.1万
  • 项目类别:
Does Ethnic Variation of the Orbit Determine the Prevalence of Horizontal Strabismus?
眼眶的种族差异是否决定了水平斜视的患病率?
  • 批准号:
    10300950
  • 财政年份:
    2021
  • 资助金额:
    $ 7.1万
  • 项目类别:
Determination of true Glia-Neuron Ratios: Validation of the Isotropic Fractionato
真实胶质细胞-神经元比率的测定:各向同性分数的验证
  • 批准号:
    8637637
  • 财政年份:
    2013
  • 资助金额:
    $ 7.1万
  • 项目类别:
CELL BIOLOGY OF SIGNALING ACROSS MEMBRANES
跨膜信号传导的细胞生物学
  • 批准号:
    8359564
  • 财政年份:
    2011
  • 资助金额:
    $ 7.1万
  • 项目类别:
Cell Biology of Signaling across Membranes
跨膜信号传导的细胞生物学
  • 批准号:
    8535803
  • 财政年份:
    2011
  • 资助金额:
    $ 7.1万
  • 项目类别:
Cell Biology of Signaling across Membranes
跨膜信号传导的细胞生物学
  • 批准号:
    7826050
  • 财政年份:
    2011
  • 资助金额:
    $ 7.1万
  • 项目类别:
Cell Biology of Signaling across Membranes
跨膜信号传导的细胞生物学
  • 批准号:
    8333430
  • 财政年份:
    2011
  • 资助金额:
    $ 7.1万
  • 项目类别:
Cell Biology of Signaling across Membranes
跨膜信号传导的细胞生物学
  • 批准号:
    8728286
  • 财政年份:
    2011
  • 资助金额:
    $ 7.1万
  • 项目类别:
Validation of the use of quantum dot-labeled proteins as biomarkers in vivo
验证使用量子点标记蛋白作为体内生物标志物
  • 批准号:
    8048240
  • 财政年份:
    2010
  • 资助金额:
    $ 7.1万
  • 项目类别:
Validation of the use of quantum dot-labeled proteins as biomarkers in vivo
验证使用量子点标记蛋白作为体内生物标志物
  • 批准号:
    8130807
  • 财政年份:
    2010
  • 资助金额:
    $ 7.1万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 7.1万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 7.1万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 7.1万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 7.1万
  • 项目类别:
    Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 7.1万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 7.1万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 7.1万
  • 项目类别:
    Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
  • 批准号:
    10699504
  • 财政年份:
    2023
  • 资助金额:
    $ 7.1万
  • 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
  • 批准号:
    10491642
  • 财政年份:
    2023
  • 资助金额:
    $ 7.1万
  • 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
  • 批准号:
    10782567
  • 财政年份:
    2023
  • 资助金额:
    $ 7.1万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了